Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Sharing ideas, information, and strategies is what Motley Fool CAPS is all about. The collective thoughts of the 170,000-plus members of the CAPS community often accurately reflect the future performance of stocks in general. CAPS stock ratings, which range from one to five stars, give the community an idea of where sentiment lies when weighing the future performance of a stock versus the S&P 500.
Nobody is perfect, however, and neither is the community. After perusing through the CAPS one-star list of projected underperformers, I came across three companies that could just as easily be five-star stocks. Here are three stocks the community may need to reconsider:
This isn't your mama's Polaroid
Investors may want to take another snapshot of Shutterfly (Nasdaq: SFLY ) before dismissing it as a one-hit wonder. Shutterfly's stock has had a tremendous run, but it is well-deserved given that no one in the photofinishing space even comes close to measuring up. Shutterfly retained 72% of its customer base last quarter while booking a 21% rise in orders.
How did its competitors fare? Eastman Kodak (NYSE: EK ) did a belly flop off the high board and Hewlett-Packard (NYSE: HPQ ) , which reported figures Tuesday, has made it quite clear that photofinishing is not a primary market share target for its business. With very little real competition, Shutterfly should continue to shine.
The community may not be jazzed about the prospects at Jazz Pharmaceuticals (Nasdaq: JAZZ ) , but the consensus figures show otherwise. Jazz may have failed to get its fibromyalgia treatment JZP-6 past the Food and Drug Administration, but sales for its narcolepsy drug Xyrem are expected to be dreamy. Jazz's five-year expected growth rate of 25% is nothing to sneeze at, nor is its sub-10 forward P/E even after its dramatic stock rise.
The company may also be attracting the attention of larger rivals. Forest Labs (NYSE: FRX ) is rich with cash and struggling to find successful drugs to replace an aging pipeline. Jazz could make for a perfect addition to its portfolio and provide instant profits to the bottom line.
Casino stocks in general are rarely in the limelight, but none deserves a second chance more than Wynn Resorts (Nasdaq: WYNN ) . Wynn absolutely obliterated consensus estimates last quarter thanks to surging growth in Macau and continued improvement in its Las Vegas hotels.
The company gets no respect despite turning a full-year profit five consecutive years. This includes 2009, a year when most casino operators, like MGM Resorts (NYSE: MGM ) , turned in monstrous losses. Every investment is essentially a gamble, but Wynn's 34% five-year projected growth rate could be a bet that always comes up black for bulls.
What's your take on these one-star stocks? Has the community missed the mark or am I missing something? Share your thoughts in the comments section below.
Track the performance of these one-star stocks and more by using My Watchlist.
- Add Shutterfly to My Watchlist
- Add Jazz Pharmaceuticals to My Watchlist
- Add Wynn Resorts to My Watchlist